中药肺岩宁颗粒调节晚期肺癌患者Th17/Treg失衡的作用  

Clinical Efficacy of Feiyanning Granule (肺岩宁颗粒) on Th17/Treg Imbalance in Patients with Advanced Lung Cancer

作　　者：殷红梅[1] 王磊[1] 龚伟珏[1] 胡晓波[1] 王中奇[1] 邓海滨[1] 肖臻[1] YIN Hong-mei WANG Lei GONG Wei-jue HU Xiao-bo WANG Zhong-qi DENG Hal-bin XIAO Zhen(Longhua Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200032, Chin)

机构地区：[1]上海中医药大学附属龙华医院,上海200032

出　　处：《中医药导报》2017年第1期34-38,共5页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：上海市卫生局科研课题计划任务(20134266);上海市中医药事业发展三年行动计划(ZY3-CCCX-2-1002)

摘　　要：目的:评估肺岩宁颗粒调节非小细胞肺癌(NSCLC)患者外周血Th17/Treg失衡的作用及Th17/Treg在疗效评价中的意义。方法:选择我院收治的60例NSCLC患者,随机分为治疗组(n=30)和对照组(n=30),同时20例健康志愿者作为健康对照组,治疗组患者口服肺岩宁颗粒治疗,对照组口服1/10剂量的"肺岩宁颗粒"进行模拟治疗,健康对照组服用生理盐水,疗程为8周。比较两组患者近期的疗效,同时以Treg细胞、Th17细胞和Th17/Treg比值为检测指标,评价肺岩宁颗粒的治疗作用和对免疫功能的调节作用。结果:治疗组有效率和疾病控制率均高于对照组。治疗前,两组外周血Treg细胞比例、Th17细胞比例和Th17/Treg比值差异均无统计学意义(P>0.05);治疗后与对照组比较,治疗组外周血Treg细胞比例明显降低(P<0.01),而Th17细胞比例和Th17/Treg比值明显升高(P<0.01)。此外,在经治疗后,无淋巴结转移的NSCLC患者Treg细胞比例显著低于出现淋巴结转移的NSCLC患者(P<0.05),而Th17细胞比例和Th17/Treg比值高于出现淋巴结转移的NSCLC患者(P<0.05)。鳞癌患者外周血中Treg细胞比例明显低于腺癌患者,而Th17细胞比例和Th17/Treg比例明显高于腺癌患者,差异均有统计学意义(P<0.05)。结论:肺岩宁颗粒对非小细胞肺癌具有一定的疗效,其作用机制与调节Treg细胞/Th17细胞比例失衡有关,并且对无淋巴结转移和鳞癌患者的治疗更为有效。Th17/Treg细胞检测可作为非小细胞肺癌疗效观察的重要客观指标。Objective： To investigate the effects of Feiyanning Granule on the imbalance of Treg/Th17 cell in peripheral blood of patients with advanced non-small cell lung cancer （NSCLC） and the significance of Th17/ Treg in the evaluation of therapeutic effects. Methods： The 60 cases of NSCLC patients treated in our hospital were randomly divided into treatment group （n=30） and control group （n=30）. Meanwhile 20 healthy volunteers were enrolled in healthy control group. Treatment group were given Feiyanning granule and control group were treated with a dose of 1/10 Feiyanning granule for 8 weeks. Healthy control group was given normal saline. The clinical efficacy were compared between the treatment and control groups and the immune function was evaluated by the calculation of Treg cell, Th17 cell and the ratio of Th17/ Treg. Results： The rate of effectiveness and control on NSCLC in treatment group were higher than those in control group. Before treatment, no significant difference of the cell number of Treg cell, Th17 cell and the ratio of Th17/ Treg was found in treatment group and control group （P〉0.05）. After treatment, compared with the conrol group, the cell ratio of Treg was signifi- cantly decreased iin treatemtn group with statistical difference （P〈0.05）, while Th17 cell and the ratio of Th17/ Treg were significantly increased with statistical difference （P〈0.05）. In addition, after treatment, the cell number of Treg in NSCLC patients without lymph node metastasis were markedly lower than NSCLC patients with lymphnode metastasis（P〈0.05）, while Th17 cell and the ratio of Th17/Treg in NSCLC patients without lymph node metastasis were higher than NSCLC patients with lymph node metastasis（P〈0.05）. Moreover, the percentage of Treg cells in the peripheral blood of patients with lung squamous cell carcinoma was significantly lower than that of the patients with lung adenocarcinoma, while the Th17 cell and the ratio of ThlT/Treg with opposite re- suhs（P〈0.05）. Conclus

关 键 词：肺岩宁颗粒 非小细胞肺癌 临床疗效 TH17细胞 TREG细胞 

分 类 号：R273[医药卫生—中西医结合]